通元针法联合祛瘀化痰清眩方治疗后循环缺血性眩晕临床研究  

Clinical Study on Combination Use of Tongyuan Acupuncture and Quyu Huatan Qingxuan Prescription on Posterior Circulation Ischemic Vertigo

作　　者：李瑞琢 丁震环 于宁 LI Ruizhuo;DING Zhenhuan;YU Ning(Department of Encephalopathy,Chinese Medicine Hospital of Puyang,Puyang Henan 457400,China;Department of Rehabilitation of Traditional Chinese Medicine,Hebi People’s Hospital,Hebi Henan 458030,China;Department of Ultrasonography,Chinese Medicine Hospital of Puyang,Puyang Henan 457400,China)

机构地区：[1]濮阳市中医医院脑病科,河南濮阳457400 [2]鹤壁市人民医院中医康复科,河南鹤壁458030 [3]濮阳市中医医院超声科,河南濮阳457400

出　　处：《新中医》2025年第7期143-147,共5页New Chinese Medicine

基　　金：河南省医学教育研究项目(WJLX2024127)。

摘　　要：目的:观察通元针法联合祛瘀化痰清眩方治疗后循环缺血性眩晕的临床疗效及对椎-基底动脉血流速度及血液流变学指标的影响。方法:选取2022年7月—2024年3月濮阳市中医医院收治的122例后循环缺血性眩晕患者,按随机数字表法分为研究组和对照组各61例。2组均给予常规治疗,对照组给予祛瘀化痰清眩方治疗,研究组在对照组基础上采用通元针法治疗,2组均治疗4周。评价2组临床疗效,比较2组治疗前后椎-基底动脉血流速度、血液流变学指标、成纤维细胞生长因子21(FGF21)及可溶性CD40配体(sCD40L)水平,观察不良反应发生情况。结果:研究组总有效率为95.08%(58/61),高于对照组81.97%(50/61)(P<0.05)。治疗后,2组基底动脉、左椎动脉、右椎动脉血流速度较治疗前升高(P<0.05),且研究组基底动脉、左椎动脉、右椎动脉血流速度高于对照组(P<0.05)。治疗后,2组全血高切黏度、全血低切黏度、血浆黏度较治疗前降低(P<0.05),且研究组全血高切黏度、全血低切黏度、血浆黏度低于对照组(P<0.05)。治疗后,2组FGF21及sCD40L水平较治疗前降低(P<0.05),且研究组FGF21及sCD40L水平低于对照组(P<0.05)。2组在治疗4周期间未出现明显不良反应。结论:通元针法联合祛瘀化痰清眩方能够改善后循环缺血性眩晕患者椎-基底动脉血流速度及血液流动性,促使FGF21及sCD40L水平恢复正常,增强疗效,且安全性高。Objective:To observe the clinical effect of the combination use of Tongyuan acupuncture and Quyu Huatan Qingxuan Prescription on posterior circulation ischemic vertigo and its effect on blood velocity of vertebrobasilar artery and indexes of hemorheology.Methods:A total of 122 patients with posterior circulation ischemic vertigo admitted to Chinese Medicine Hospital of Puyang from July 2022 to March 2024 were selected and divided into the study group and the control group according to the random number table method,with 61 cases in each group.Both groups were given conventional treatment,the control group was additionally treated with Quyu Huatan Qingxuan Prescription,and the study group was additionally treated with Tongyuan acupuncture based on the treatment of the control group.Both groups were treated for four weeks.After treatment,the clinical effects were evaluated;the blood velocity of vertebrobasilar artery,indexes of hemorheology,levels of fibroblast growth factor 21(FGF21)and soluble cluster of differentiation 40 ligand(sCD40L)were compared before and after treatment in the two groups;the incidence of adverse reactions was observed.Results:The total effective rate was 95.08%(58/61)in the study group,higher than that of 81.97%(50/61)in the control group(P<0.05).After treatment,the blood velocity of basilar artery,left vertebral artery and right vertebral artery in the two groups was respectively elevated when compared with those before treatment(P<0.05),and the blood velocity of basilar artery,left vertebral artery and right vertebral artery in the study group were higher than those in the control group(P<0.05).After treatment,the whole blood high-shear viscosity,whole blood low-shear viscosity and plasma viscosity in the two groups were reduced when compared with those before treatment(P<0.05),and the whole blood high-shear viscosity,whole blood low-shear viscosity and plasma viscosity in the study group were lower than those in the control group(P<0.05).After treatment,the levels of FGF21 and sCD40L in

关 键 词：后循环缺血性眩晕 通元针法 祛瘀化痰清眩方 椎-基底动脉血流速度 血液流变学 成纤维细胞生长因子21 可溶性CD40配体 

分 类 号：R441.2[医药卫生—诊断学]